How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Original language	English
Journal	British Journal of Haematology
DOIs	https://doi.org/10.1111/bjh.17185
Publication status	E-pub ahead of print - Oct 2020

Keywords

@article{90498232cb5d4b9f867294056e80473b,

title = "How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).",

keywords = "AML, NPM1 mutations, molecular MRD",

author = "R Dillon and N Potter and S Freeman and N Russell",

year = "2020",

month = oct,

doi = "10.1111/bjh.17185",

language = "English",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley",

}

TY - JOUR

T1 - How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).

AU - Dillon, R

AU - Potter, N

AU - Freeman, S

AU - Russell, N

PY - 2020/10

Y1 - 2020/10

KW - AML

KW - NPM1 mutations

KW - molecular MRD

UR - http://europepmc.org/abstract/med/33058194

U2 - 10.1111/bjh.17185

DO - 10.1111/bjh.17185

M3 - Article

C2 - 33058194

SN - 0007-1048

JO - British Journal of Haematology

JF - British Journal of Haematology

ER -